# Filing Detail

Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-21-051861
Filing Date
2021-04-19
Accepted
2021-04-19 14:04:57
Documents
4
Period of Report
2021-06-01

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | DEF 14A | tm212636d1_def14a.htm | DEF 14A | 393626
2 | GRAPHIC | tm212636d1_def14aimg001.jpg | GRAPHIC | 428551
3 | GRAPHIC | tm212636d1_def14aimg002.jpg | GRAPHIC | 507889
4 | GRAPHIC | tm212636d1_def14aimg003.jpg | GRAPHIC | 14582
| Complete submission text file | 0001104659-21-051861.txt |  | 1705083

Mailing Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312
Business Address 1055 WESTLAKES DRIVE, SUITE 300 BERWYN PA 19312 610-727-3913
Annovis Bio, Inc. (Filer) CIK: 0001477845 (see all company filings)

EIN.: 262540421 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-39202 | Film No.: 21834016
SIC: 2834 Pharmaceutical Preparations